Appointments

NEOMED has added two new members to its board of directors. Joining the board are Dr. Laurence Rulleau, principal at CTI Life Sciences, and Paul Buron, executive vice president and chief fi nancial offi cer of the Business Development Bank of Canada (BDC). Prior to joining CTI, Dr. Rulleau served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. She worked at different fi rms including Desjardins Securities, Yorkton Securities and Blackmont Securities. She was involved in numerous mergers and acquisitions as well as IPOs. More recently she served as vicepresident business development of Univalor, the technology transfer offi ce of Montréal’s university and affi liated schools. Under her responsibility at Univalor in the last three years, more than 40 licences with the industry were signed and eight companies started. Mr. Paul Buron has been the executive vice president and chief fi nancial offi cer of the BDC since 2006 and assumed the additional title of chief risk offi cer in 2015. He has over 30 years of experience in fi nance. Before joining BDC, he held leadership positions in major corporations, such as the Société générale de fi nancement du Québec, Donohue Inc. and the TVA Group Inc.

Verlyx Pharma Inc. has named Dr. Patrick Colin as its new chief development offi cer. Dr. Colin had been a consultant with Verlyx since 2011 overseeing the clinical development and pharmacovigilance activities of the company. He has spent more than 12 years at Axcan Pharma (today Aptalis Pharma), where he established and led the drug development department as vice-president, R&D. His credentials include 27 years of global drug development experience, and more than 15 market approvals in the US, EU, Canada and Australia. During his career, and especially during his Axcan years, Dr. Colin built strong ties with the international hepatology community, and played a key role in the development and approval of liver drugs such as ursodiol in the treatment of Primary Biliary Cirrhosis.

Dr. Michael Toth has taken the helm of the Ontario Medical

Become a certified chemical technologist (cct)

cCT certification offered by the Canadian Society for Chemical Technology (CSCT) • Is recognized nationally by employers • Is based on Canada-wide technology standards • Allows for greater career mobility

CSCT members in good standing who have attained the required combination of education and experience in chemical technology need only apply once for the cCT for the one time fee of $25 plus tax. Certification remains valid as long as CSCT membership is maintained.

for more information or to apply go to www.chem-tech.ca/cct

Dr. Michael Toth

Association as its new president. Dr. Toth is a family physician from Aylmer, a small town in southwestern Ontario, who has practiced for nearly 30 years. He is also the medical director at a long-term care facility and a member of the Medical Advisory Committee at the St. Thomas Elgin General Hospital. Dr. Toth is the 134th president of the OMA; he takes over from Dr. Ved Tandan, a surgeon from Hamilton. He will serve for a one-year term.

Dr. Michel Goldman, former executive director at the Innovative Medicines Initiative (IMI), is the newest member of CQDM’s board of directors. Goldman led the IMI from 2009 to 2014 and was highly successful with this major European initiative. Under his leadership, the IMI created nearly sixty publicprivate consortia to meet pressing needs in areas of great importance as antimicrobial resistance, Alzheimer’s disease, autism, diabetes, immuno-infl ammatory diseases, chronic lung diseases and drug safety. A professor of immunology at the Université Libre de Bruxelles (ULB) in Belgium, he has also served as head of the department of Immunology-Hematology-Transfusion at the Hôpital Erasme in Brussels and as director of the ULB Institute for Medical Immunology. His scientifi c achievements have resulted in more than 400 articles in peer-reviewed journals. In 2006, he was also recognized by the Thomson Institute for Scientifi c Information (ISI) as one of the most cited scientists.

Clinical-stage company Aptose Biosciences Inc. has added Dr. Michael Andreeff to its scientifi c advisory board. Dr. Andreeff joins Brian Druker, M.D., director, Oregon Health & Science University (OHSU) Knight Cancer Institute and Daniel D. Von Hoff, M.D., physician-in-chief and distinguished professor of Translational Research at Translational Genomics Research Institute (Phoenix, AZ), as scientifi c advisors for Aptose. Dr. Andreeff received his M.D. and Ph.D. degrees at the University of Heidelberg, Germany, and additional training and faculty appointments at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY, in the Departments of Pathology and Leukemia. Dr. Andreef is professor of medicine and holds the Paul and Mary Haas chair in Genetics at MDACC. He has received uninterrupted funding from the National Cancer Institute (NCI) for more than 30 years, serves as the principal investigator (PI) of a grant entitled “The Therapy of AML”, and participates as a PI in research grants focused on leukemia, lymphoma, ovarian and breast cancer, among others. He has published more than 450 peerreviewed papers, fi ve books and 75 book chapters.

Serge Maltais is stepping into the role of president and CEO of

Serge Maltais

Héma-Québec effective May 18. Serge Maltais brings extensive experience in operations management from his positions with major pharmaceutical companies. Before joining Héma-Québec, he was vice-president, Supply Chain, for commercial operations at Sandoz Canada Inc., the Canadian pharmaceutical subsidiary of Novartis A.G. specializing in generic products. He joined Sandoz in 2002 and was responsible for customer service, sales forecasting, purchasing and distribution for Canada. From 1985 to 2002, he held various management positions with the Canadian subsidiary of Baxter International, where he proved to be a highly successful leader in the areas of logistics and production. He holds a Bachelor of Industrial Engineering degree from the École Polytechnique de Montréal and a diploma in Business Administration from the Université de Sherbrooke.